Skip to main content
OpenTrials
Completed

NCT Number: NCT01195766

Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed.

In the same way, mortality, global survival and free-progression survival after O-ESHAP treatment and TAPH will also analyzed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Loading trial locations.

About this study

In addition to the above:

  • To asses the complete response rate after O-ESHAP.
  • To asses the toxicity of O-ESHAP regimen
  • To asses the stem cells mobilization capacity of O-ESHAP regimen
  • To evaluate the final results of the whole procedure (O-ESHAP followed by high-dose chemotherapy and ASCT): transplant-related mortality (TRM), overall survival (OS), and progression free survival (PFS)
  • To investigate the correlation between the overall response and CD20 expression by tumoral cells.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with histologically confirmed relapsed, partial response or refractory classical HL after first line chemotherapy. They will be included irrespective of CD20 expression on HRS cells. CD20 expression will be analyzed on all available biopsies and this data will be recorded for further evaluation.
  • Age 18 to 65 years. Patient >65 and <70 years old with ECOG < 2 and absence of comorbidities will be included in the study if considered adequate by the investigator.
  • Leucocytes > 3,0 x 109/L and platelets > 100 x 109/L.
  • ECOG < 2.
  • No major organ dysfunction.
  • Written informed consent.
  • HIV negative.
  • No active hepatitis B or C infection.
  • Availability of histological report of biopsy at diagnosis or at relapse and availability of biopsy to be revised by reference pathologists.
  • Absence of other neoplasia, except basocellular tumor or carcinoma of the uterine cervix in situ.
  • Contraception measures in fertile females.

Exclusion criteria

  • Subjects who have current active hepatic or biliary disease
  • presence of pathology that would contraindicate the administration of chemotherapy
  • HIV positive
  • Hepatitis B or C infection
  • history of other malignancies in addition to those specified in the inclusion criteria
  • informed consent not signed
  • Pregnant and / or breast-feeding or reproductive capacity adults who do not use an effective method of birth control during study treatment and at least six months later. An effective method is that used at least one barrier mechanism.

Treatment and study plan

ofatumumab

Drug

Ofatumumab in addition with ESHAP therapy

Other names: ARZERRA

Primary outcomes

  1. Analysis of the global response rate (complete responses + partial responses) after O-ESHAP treatment

    Time frame: 4 years follow-up

Secondary outcomes

  1. To analyze the complete response rate after O-ESHAP treatment. Further secondary outcomes as described in study summary

    Time frame: 4 years follow-up

Sponsors and collaborators

Lead sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Other

Registry information

Official study title

Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment

Important dates

Study start
2010
Primary completion
2013
Study completion
2015
First posted
Sep 6, 2010
Registry last updated
Feb 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.